
Researchers at Boston University and Banner Health identified a specific protein marker in blood samples that accurately detected advanced CTE in 21 deceased football players.
Two studies published in the medical journal JAMA report that a new blood test has the potential to detect advanced stages of chronic traumatic encephalopathy (CTE) in living patients. Research conducted by Boston University and Banner Health examined blood samples from 21 deceased football players, including 12 professionals, seven college players, and two high school athletes. Autopsies later confirmed that the majority of the professionals, four college players, and one high school player had advanced-stage CTE, which correlated with higher concentrations of a specific protein marker in their previously collected blood samples.
The study found that the five players diagnosed with both CTE and Alzheimer’s disease exhibited the highest levels of the identified protein. While the test showed promise in identifying advanced stages of the degenerative brain illness, it did not detect early-stage CTE, which is often symptom-free. Patients in the advanced stages typically present with memory loss, confusion, depression, and severe mood swings.
A separate 11-case study from the Washington University School of Medicine in St. Louis, published on November 13, 2026, identified the same blood biomarker. Michael Alosco, co-senior author of the Boston University study, noted that while the research is in the discovery phase with a small sample size, the test could allow for high-accuracy detection and future clinical trials within the next five years. Currently, the U.S. Food and Drug Administration has not approved any specific tests or treatments for CTE, which has historically only been diagnosable after death.
Stay informed
Follow SportsNow.
Join the reader list for future briefings and important newsroom updates.
Reader conversation